Therefore, this study aimed to search potential efficacy biomarkers for EGFR-TKI resistant NSCLC patients who received ICI plus chemotherapy from the perspective of immune cells in peripheral blood. This evidence concerns the gene EGFR and non-small cell lung carcinoma.